Winnie Z Y Teo, Ian Y E Ong, Jason W Y Tong, Wan Li Ong, Adeline Lin, Fangfang Song, Bee Choo Tai, Melissa Ooi, Cinnie Yentia Seokojo, Yunxin Chen, Chandramouli Nagarajan, Wee Joo Chng, Sanjay de Mel
PURPOSE OF REVIEW: The development of potent novel agents has improved outcomes for patients with multiple myeloma (MM). Heterogeneity of response to therapy, an expanding arsenal of treatment options, and cost are however major challenges for physicians making treatment decisions. Response-adapted therapy is hence an attractive strategy for sequencing of therapy in MM. Despite its successful application in other haematologic malignancies, response-adapted therapy is yet to become a standard of care for MM...
October 2023: Current Hematologic Malignancy Reports